Influenza Surveillance in Tamil Nadu, India: New Research Highlights Gaps and Opportunities
A new study on influenza surveillance in Tamil Nadu, India, has shed light on the substantial burden of influenza-like illness (ILI) and severe acute respiratory infections (SARI) on the healthcare system and community. The research, conducted by the ICMR-National Institute of Epidemiology, analyzed the strengths and gaps in ILI/SARI surveillance in four districts of Tamil Nadu. The findings indicate that ILI/SARI surveillance remains a seasonal event, with a gap in awareness among health workers. The study emphasizes the need for year-round reporting of cases, prioritization of testing for influenza, and development of infrastructure for testing novel pathogens.
Key Takeaways:
- The study was conducted in four districts of Tamil Nadu, India, and included 85 healthcare facilities, 23 laboratories, and 376 stakeholders.
- 44 (51.8%) healthcare centers reported ILI/SARI cases, while 36 (42.4%) healthcare centers collected samples.
- 25 (29.4%) healthcare facilities had at least one medical officer and 23 (27.1%) had at least one allied health staff who received training for ILI/SARI surveillance.
- The study highlights gaps in awareness among health workers and the need for year-round reporting of cases.
- The research emphasizes the importance of prioritizing testing for influenza and developing infrastructure for testing novel pathogens.
- The study also notes that current guidelines for ILI/SARI surveillance are in place, but there is a need for better awareness and training among health workers.
Statistics:
- 376 stakeholders were involved in the study.
- 44 (51.8%) healthcare centers reported ILI/SARI cases.
- 36 (42.4%) healthcare centers collected samples.
- 25 (29.4%) healthcare facilities had at least one medical officer.
- 23 (27.1%) healthcare facilities had at least one allied health staff who received training for ILI/SARI surveillance.
Sources:
- ICMR-National Institute of Epidemiology
- Discover Health Systems
- Springer Nature
- DOI: 10.1007/s44250-025-00255-1
- Medical Letter on the CDC & FDA, July 13, 2025.